Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (6): 1004-1009    DOI: 10.31083/j.ejgo.2020.06.5462
Original Research Previous articles | Next articles
Low-grade serous ovarian carcinoma is a rare histological subtype in Japan
Hideki Iwahashi1, Morikazu Miyamoto1, *(), Takahiro Sakamoto1, Hiroki Ishibashi1, Soichiro Kakimoto1, Hiroko Matsuura1, Hitoshi Tsuda2, Masashi Takano1
1Department of Obstetrics and Gynecology, National Defense Medical College Hospital, 359-0042 Saitama, Japan
2Department of Basic Pathology, National Defense Medical College Hospital, 359-0042 Saitama, Japan
Download:  PDF(3172KB)  ( 85 ) Full text   ( 3 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose of investigation: To compare low-grade serous ovarian carcinomas (LGSC) and high-grade serous ovarian carcinomas (HGSC). Materials and Methods: Between 1985 and 2013, patients with LGSC and HGSC were identified through pathological review using the 2014 World Health Organization classification. The clinical outcome of patients with LGSC and HGSC was retrospectively compared. Results: A total of 174 cases, 5 (2.9%) cases of LGSC and 169 (97.1%) cases of HGSC (97.1%) were identifies for our study. The proportion of patients who underwent optimal surgery was higher for LGSC than HGSC (p = 0.03). We found no other statistically significant differences in the characteristics of the two groups. Survival analysis revealed that the histological subtype was not an independent prognostic factor of Progression-free survival (p = 0.28) or overall survival (p = 0.43). Conclusions: LGSCs may be a rare histological subtype in Japan and may not be associated with a different prognosis than HGSC. Larger scales studies are needed to examine the clinical significance of LGSC.
Key words:  Ovarian carcinoma      Ovarian serous carcinoma      Low grade serous carcinoma      High grade serous carcinoma      Prognosis     
Submitted:  02 January 2020      Accepted:  03 June 2020      Published:  15 December 2020     
*Corresponding Author(s):  MORIKAZU MIYAMOTO     E-mail:  morikazu1118@hotmail.co.jp

Cite this article: 

Hideki Iwahashi, Morikazu Miyamoto, Takahiro Sakamoto, Hiroki Ishibashi, Soichiro Kakimoto, Hiroko Matsuura, Hitoshi Tsuda, Masashi Takano. Low-grade serous ovarian carcinoma is a rare histological subtype in Japan. European Journal of Gynaecological Oncology, 2020, 41(6): 1004-1009.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.06.5462     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I6/1004

[1] Haci Ozturk Sahin, Zelal Aydin, Ibrahim Ugras Toktas, Cetin Toraman, Ilkbal Temel Yuksel, Alper Seyhan, Ozgur Akbayir. Clinical and prognostic value of pre-operative systemic inflammatory markers in clinical course and prognosis of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 924-930.
[2] Rosie Clare, David Agbamu, Radhakrishnan Jayan, Eliyaz Ahmed. Primary peritoneal cancer presenting with widespread lymphadenopathy, radiologically mimicking lymphoma[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 1061-1064.
[3] Wook Youn Kim, Shin Hee Seo, Seung-Hyuk Shim, Jin Hee Park, Hyung Kyu Park, Kyeong A So, Tae Jin Kim, Sun Joo Lee. Correlation of immunohistochemistry and silver in situ hybridization for the assessment of c-MET in uterine cervical cancer patients treated with radical hysterectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 745-752.
[4] Qianqian Tang, Shi Wan, Xiaogai Qiao, Fang Wang, Yan Wang. MiR-29 promotes ovarian carcinoma cell proliferation through the PTEN pathway[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 774-778.
[5] Chados Nikolaos, Gregoriou Odysseas, Salakos Nicolaos, Kondis Agatha, Deligeoroglou Efthymios. The prognostic significance and immuno-expression of survivin, mutant p53 and bcl-2 in 92 cases of epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 517-522.
[6] Sun Yi Choe, Jung-Woo Park. Prognostic significance of the number of metastatic lymph nodes in early cervical cancer: a retrospective study[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 536-540.
[7] Yuqing Yang, Huimin Zhang, Weiming Chen, Xiaoyue Chen, Xiaolin Yu. Lapatinib promotes ovarian cancer cell apoptosis through mROS-HtrA2/Omi pathways[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 598-603.
[8] B.-H. Zhang, L. Li, J. Ji, J. Guo, X.-L. Zhou, H. Xu, F. Cao, X.-H. Tong. Prognostic value of Foxp3+ regulatory T cells in endometrial cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 339-342.
[9] H. Ishibashi, M. Miyamoto, T. Aoyama, H. Soyama, H. Matsuura, H. Iwahashi, M. Takano, K. Furuya. The effect of six scheduled cycles of neoadjuvant chemotherapy on prognosis in advanced ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 386-390.
[10] Jingyuan Wang, Xiaoping Li, Danhua Shen, Xiao Wang, Zhiqi Wang, Jianliu Wang. Clear-cell carcinoma of the endometrium:type I or type II endometrial carcinoma?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 449-454.
[11] T. Sakamoto, M. Miyamoto, T. Kono, H. Tsuada, H. Matsuura, T. Aoyama, M. Takano, K. Furuya. Endometrial dedifferentiated carcinoma: a case report. Pathological review at a single institution and systematic review of published literature[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 163-166.
[12] X.Q. Wang, S.Q. Ma, J.Y. Guo, F. Zhao, X.H. Liang. Characteristics and prognostic factors among premenopausal versus postmenopausal patients with advanced endometrial cancer: a SEER-based analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 1-6.
[13] Y. Murata, Y. Miyahara, K. Suzuki, S. Wakahashi, T. Sudo, S. Nagao, S. Yamaguchi, Y. Ebina, H. Yamada. Leukocytosis and thrombocytosis as prognostic factors for women with uterine cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 93-97.
[14] S. Kalogeropoulos, E. Chronopoulou, E. Kourea, A. Siampalis, A. Kaponis, G. O Decavalas. Small cell ovarian carcinoma hypercalcemic type and endometrial adenocarcinoma in a 49-year-old patient: a very rare case[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1064-1066.
[15] S. Cierniak, R. Koktysz, M. Jesiotr, A. Gąsowska-Bodnar, L. Bodnar. Expression of the PI3K/AKT/mTOR pathway as a prognostic factor in patients with advanced high grade serous ovarian carcinoma treated with neoadjuvant chemotherapy[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 744-751.
No Suggested Reading articles found!